Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Public ClinicalTrials.gov record NCT01463397. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: To assess the efficacy of SAR292833 versus placebo in reducing pain intensity associated with chronic peripheral neuropathic pain using 11-point numerical rating scale (NRS). Secondary Objectives: * To compare the effects of SAR292833 with placebo on the change of neuropathic pain symptoms versus baseline Neuropathic Pain Symptoms Inventory (NPSI); * To evaluate the effects of SAR292833 in comparison to placebo on the change in pain intensity of mechanical allodynia; * To investigate the safety and tolerability of SAR292833 in comparison to placebo; * To investigate the pharmacokinetics (PK) and the relationships between main efficacy parameters or pharmacodynamic effect (PD) and pharmacokinetics (PK/PD) of SAR292833 in patients with chronic peripheral neuropathic pain.
Study identification
- NCT ID
- NCT01463397
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 191 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2012
- Primary completion
- Apr 30, 2013
- Completion
- Apr 30, 2013
- Last update posted
- Feb 25, 2016
2012 – 2013
United States locations
- U.S. sites
- 28
- U.S. states
- 15
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840014 | Tucson | Arizona | 85741-3565 | — |
| Investigational Site Number 840007 | Garden Grove | California | 92845 | — |
| Investigational Site Number 840020 | Newport Beach | California | 92660 | — |
| Investigational Site Number 840038 | Santa Ana | California | 92705 | — |
| Investigational Site Number 840002 | Tustin | California | 92780 | — |
| Investigational Site Number 840046 | Coral Gables | Florida | 33134 | — |
| Investigational Site Number 840013 | Ocala | Florida | 34471 | — |
| Investigational Site Number 840034 | Palm Beach Gardens | Florida | 33418 | — |
| Investigational Site Number 840019 | Evansville | Indiana | 47714 | — |
| Investigational Site Number 840012 | Indianapolis | Indiana | 46254 | — |
| Investigational Site Number 840042 | Framingham | Massachusetts | 01702 | — |
| Investigational Site Number 840004 | Springfield | Massachusetts | 01104 | — |
| Investigational Site Number 840035 | St Louis | Missouri | 63141 | — |
| Investigational Site Number 840010 | Las Vegas | Nevada | 89148 | — |
| Investigational Site Number 840037 | Albuquerque | New Mexico | 87109 | — |
| Investigational Site Number 840040 | Hartsdale | New York | 10530 | — |
| Investigational Site Number 840001 | New York | New York | 10032 | — |
| Investigational Site Number 840033 | Rochester | New York | 14618 | — |
| Investigational Site Number 840015 | Raleigh | North Carolina | 27612 | — |
| Investigational Site Number 840022 | Winston-Salem | North Carolina | 27103 | — |
| Investigational Site Number 840017 | Toledo | Ohio | 43623 | — |
| Investigational Site Number 840044 | Altoona | Pennsylvania | 16602 | — |
| Investigational Site Number 840018 | Johnstown | Pennsylvania | 19505 | — |
| Investigational Site Number 840045 | Tullahoma | Tennessee | 37388 | — |
| Investigational Site Number 840006 | Austin | Texas | 78731 | — |
| Investigational Site Number 840043 | Dallas | Texas | 75230 | — |
| Investigational Site Number 840032 | Dallas | Texas | 75231 | — |
| Investigational Site Number 840016 | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01463397, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 25, 2016 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01463397 live on ClinicalTrials.gov.